this And X. Thank you own you, on slides. platform, Slide to to on currently just your we're the advance need listeners And Raju. remind
IL-XX/IL-XX, target Phase And to And the goals maximize emergence regimens QD to exposure to and determine specifically, So XX study, dosing the and study TYKX direct X and day in coverage BID what IC-XX the and to exposure between be coverage TYK X interleukin are of it's X of finally, to VTX-XXX really interferon-alpha terms with to covered. Phase establish hours this engagement Day I'll various mediated cytokines, validated from ascending to cohorts indications. Deucravacitinib VTX-XXX. note through X the that Phase of ex-vivo And and TYKX have pharmacodynamic of profile demonstrate both in-vivo in with the evaluate all panel very show assays studies academic exposure in dose results multiple read dosing safety the through healthy safety volunteer driven in our trials this dose assays. cohorts Phase the and of in demonstrated per of by target well clinical the coverage and target the subjects correlation of that in
Next XX. Slide slide,
that So summary show what's These of safety, up data coverage. the target to I'll really the and exposure you? roll
all were events classified few VTX-XXX. events Firstly, in which the of VTX-XXX all drug review as mild. Allosteric dependent a there inhibitors frequency relative no this tolerated minimal was SAD/MAD adverse dose adverse the in adverse and to VTX-XXX trends will well other events, target minutes. I TYKX And across treatment is observed were with related emergent was cohorts, off There
saw meaning TYKX we dose robust for XX pathway activity efficient clinic. IC-XX hours exhibits in greater TYKX dependent coverage no the that in the up that pharmacodynamic class limiting enable supporting differentiated hypothesis leading in-vivo may with in coverage, IC-XX VTX-XXX dose in we And toxicities. achieve to finally, assays ex-vivo efficacy Secondly,
Phase of dosing received dose this cohort and administered the XX was single the was XXX Then out levels. a milligrams, wash study occurred to VTX-XXX. and to per for had is each There at the Moving placebo. an challenge redoes of dose schema of as this six VTX-XXX interferon-alpha ascending the eight X subject were ranging to active On from dose with seven XX. subjects This a Slide a levels suspension. seven milligrams and time part each single
interest. of through right mild was as significant lower were cohorts. concern dosing. all events were and well the VTX-XXX clinical laboratory in classified adverse All no There pharmacodynamic was temporal relationship Looking the events tolerated observed. seven response adverse to as no there simulation area detailed signaling because ex-vivo results by and to was measured greatest is the going IL-XX effects ascending doses not really multiple interferon study the and challenge interferon-alpha show following the of I'm gains,
Moving to now Slide XX.
the schema multiple dose study. ascending Here's the for
the these milligrams coverage. at and to cohorts, tolerability five dose pre between see per dose with milligrams XXX an for transcriptome dose stimulation in-vivo alternating days. placebo. XXX included can studied QD cohort analysis You therapeutic primary these milligrams we in And at The the safety BID targets measure Pharmacodynamic dose XXX interferon-alpha five And the tech TYKX cohorts, milligrams objective for then BID. XX, interferon-alpha IC-XX was XXX IL-XX/IL-XX baseline BID eight cohorts and QD, the the an concentration day determine of genes XX and BID, subjects day Again, for were coverage on analyses for stimulation both correlation and ex-vivo XX. target post done XX. challenge. and and IC-XX secondly, to responsive And and
interferon-alpha the on cohort that interferon causes itself did we was four, adverse stimulation lot XX, As see I shortly, up day noted, you'll through of a events. the as
interferon and final the the challenge do didn't score. we So
we're across this, Moving on really to coverage Slide the XX. and you cohorts. the focused to want exposure target now to I orient
interleukin at For XX and hours make for you're these doses, bit you four have other IC-XX see sure interferon-alpha. of we'll you coverage When XX, of the you targets IC-XX coverage all a looking coverage, XX, which and QD and What this interleukin compounds, coverage, to really and two covered. being that nine IL-XX, little just these of six of can with this and that or IL-XX you that three, compare for more to are interferon-alpha. to here, hours begin the TYKX IC-XX just see even are understanding can contrast
up the XXX As doses you to and go BID XXX.
XX hours have coverage and for for IC-XX for hours interferon-alpha. And we that of coverage IL-XX IC-XX. IL-XX see can and results to IL-XX similar You XX of
XX interferon-alpha see if we of when The achieved the exposures that coverage. with or and safety So suppression and up to IC-XX coverage lasts demonstrate roll this class XX to and together, you file monoclonal approach like leading we biologic IC-XX IL-XX hours here like pathways. IL-XX/IL-XX
to Slide XX. Moving
to transition let's safety now the So assessment.
minimal were there adverse related events There were drug dose interruptions. and related classified discontinued adverse no the were All as of events no no patients emergent the frequency therapy, adverse of there There no mild serious treatment were observed. events, in were trends skin dose contrast Phase subcutaneous number in just dermatologic Allosteric that XX%. events, to inhibitors we patients trial. in a of other disorders a the in That's few and X were TYKX adverse three total and Remember that the reported minutes. as compare
in TYKX no Lipid classified are ability as adverse up drug believe not There a XX observed and best that the infections, context the coverage We achieve with class these a with of in Slide cytopenia’s XX. were related. data are consistent favorable therapeutic All safety events hours abnormalities. for of IC-XX window these potential to cheat to profile.
such you this interferon some a reporting who then challenge. papules. lot continued we're to adverse Then adverse a This BID results assessment, after events. headaches, which subsequent really challenge of out cheek with VTX-XXX smattering cytopenias XXX topical day so were were can dosing the to the side This you patients a time drug safety And split right therapy pre-interferon the dismissing. there had related. and the manifestation that and tiny rash be in no in so details we potentially papule did is patients XX. the related partway drug relationship. the divided on smile two skin show adverse this through the almost you had three clear related for We not faeces, that the that slide occurred want at being until effects. event judge the lower challenge a of up see papule XXX-QD Here's have Interferon-alpha through a was effects better skin patients into lesion. any I can to side soft cohort Walking the cohort also of interferon of a the events causes not there on see is There goes thing
again, VTX-XXX. that Again, but VTX-XXX subjects were no those, capsules. with no drug-related, improved dosing with mild and of patches continued subjects these resolve One did to That resolved dosing. lesions not and papules were faeces judged continued therapies success topical faeces not completely with be that TEAEs mild topical mild therapies. one had
Finally, there patient elevations, transamination was mouth COVID-XX with section. patients were mild liver of pain. and judged and as a abdominal some that has one in the occurred dry were There context these
Slide Moving XX on Slide to -- XX. or
a interferon-alpha that resolved adverse there that patient in placebo see can just had with was they're the that are things the Here they to after the events expect occurred frequently, you see challenge, dose, would and sorts thereafter. ALT both interferon-alpha, after VTX-XXX. one which of And occur rise interferon-alpha and you
XX. Slide to on Moving
time were the lymphocytes, potentially changes fossil or there Looking trapping no in findings, changes kinase hematologic hemoglobin chemistry and in no over changes no JAK panel, and neutrophils, platelets, and at related, Lipid’s.
Slide XX. to on Moving
the descendant effects. safety we transitioning now, dependent wrote dose robust So pharmacodynamic from to pharmacodynamic effects, saw
all you IL-XX/IL-XX stimulation complete dual interferon imply time can TYKX dose signaling. IL-XX of left suppression share This signaling And the dependent the IL-XX/IL-XX suppression On of data I received IL-XX see of points. at beta-X. IL-XX heterodimer specific inhibition that complete these note gamma, all are after
believe IL-XX we indicates IL-XX signaling, you and this the the inhibition that signaling also of inhibition below. can data So, in graph see of
through inhibition impact inhibition In on related is you XXX the for the percentage all for the most what you and ISG-XX, exposure activity day responsive and response right placebo mediated the genes. we the expressed table downstream can resolution dose of to including onset and genes. display three IFI-XX. really relative product amplitude are inhibition all diverse CXCL-XX, genes to targets saw and of can milligram these through could dose, cohorts robust of of And genes These tested. the is BID kinetics, an direct tech interferon-alpha TYKX all side, in three below, there's Moving potent app also dramatic and see a genes, see the as pharmacodynamic
Slide to on Moving XX.
summary, in target and believe demonstrated So class coverage differentiation deucravacitinib with other we've TYKX and allosteric excellent VTX-XXX margins. versus safety demonstrated inhibitors. we that exposure leading the
coverage safety a suppression Phase safe of target the achieved and note of sustained biologic therapeutic IL-XX/IL-XX of study. TYKX and is IL-XX/IL-XX in and antibodies IC-XX inhibitor or window with interferon-alpha. the VTX-XXX allosteric VTX-XXX hours. to terms and like TYKX for In broad There's X coverage demonstrate IC-XX only coverage from MAD XX we that monoclonal pathways,
Moving on looking few minutes strategy to for the XX, spend now differentiation and a Slide development we’ll at VTX-XXX.
XX. Slide to on Moving
psoriatic never inhibition versus in milligrams IC-XX but VTX-XXX more particularly profile six this allosteric coverage. improved nine the just including the another with terms were these gram part toxicities curves So and a expected see deucravacitinib IC-XX, drive toxicities. that day time fuller relative at a hours expect TYKX have VTX-XXX let's improved the we'd limited generation and window, Phase disease well that the is IC-XX would see get first pathway you of to to This acne therapeutic of coverage in dose can have as be dependent about on necessary, like dose by improved for into as concentration psoriasis would window the only and a achieves and be therapeutic psoriasis differentiate deucravacitinib day dose. what not meaning that especially once coverage Deucravacitinib like differentiation IC-XX/IC-XX to deucravacitinib vs of with is of inflammatory the may above bowel as be deucravacitinib no arthritis. in coverage. that And coverage deucravacitinib can And There's psoriasis about day, inhibitors milligram greater a efficacy And think very an to but skin dose. the an opportunity drive a expected high for coverage you XX-milligram dose rash for we indications and such of improved into and left, to six to once IC-XX also exposure doses both of six-milligram dose. the IC-XX I'll could and IC-XX achieves are slide, that indication that And QD X of efficacy, TYKX
slide, Next Slide XX.
little table let's bit, target the the second on and the focus the coverage right a you into on I'm details adverse going to to initially line. the get of So skin events
Phase day From challenge So our study data these deucravacitinib with a this healthy the are XX-day on volunteers. XX. MAD interferon-alpha X, and is reminder,
seeing same context or you the what QD, rolled as XX% up XX-day And exactly XX% So once in adverse get to BID of a saw. to study, skin XX the milligrams X events. we milligrams you're
you of to are almost go minutes And patients. milligrams, showed of you it's remind or down to skin by you few that or and sort VTX-XXX, trials, and Phase XX%. can for six three acne the you of if I ago Then a XX%. you clinical range. rolled studied, QD can manifestations As with were up milligram across have BID, rash that look the ID, to Phase that X% stay XX% you if up XX doses various contrast X see X% milligrams the all X that in you I'll the it's dose,
the X%, skin or milligrams lupus, these and together, at in doses. at was both up where lupus milligrams you BID with of XX% it's manifestations can the X of of range, three the BID, with they QD, all patients you X%, But XX% see X% trial XX rash all you've reported acne Although often milligrams to getting when then and still skinnies you're in it if XX%. get looked
QD, then has having in hours for coverage. and hours zero IC-XX you hours six of you're for And zero just to milligrams to XX nine So BID QD hours and dose even remind of of XX coverage coverage you, IC-XX. up and IC-XX milligrams get milligram as X TYKX the IC-XX
very coverage dermatologic significant And you see with what dependent dose events. adverse different VTX-XXX. than So yet
potential dose potentially VTX-XXX frequencies for without we've X achieved TYKX coverage And that IC-XX high that elicits skin per day. exposures skin believe data dose a with window, demonstrates greater that than dependence findings meaning therapeutic establish So best-in-class We robust events. skin milligrams high contrast frequent that we occur by and versus adverse differentiation deucravacitinib The the note toxicities. limiting a deucravacitinib. and these
XX. Slide slide, Next
three inhibitor set level This want data. allosteric TYKX I X you here. Phase comparing to different is So
challenge start So XX at interferon-alpha with trials and the a healthy Day volunteers VTX-XXX. of the trials. we'll are end with back And these
per looked just that daily to patients, XXX-day remind was XXX one in rash day single dose papular total was under at XX%. were but I'll These not subcutaneous at saw a and milligrams milligrams related rash three we and skin we So all XXX disorders doses therapy. that from that the of ranging judged those papular you resolved
So COVID and quite had the single Trans were with mild infection. low the AEAES context manifestations a patient of skin we in elevated that
the relevant If doses BID. you look at clinically of XXX BID and XXX
IC-XX have coverage. XX IC-XX hours XX of We hours and of and XX coverage respectively,
They XX Now At skin start the XX%. Phase dose milligrams milligrams of coverage dose ranges from let's deucravacitinib. the zero was at couple relevant of see compound. were in healthy dose. right looked to QD XXX rash of XX% subcutaneous XX total on coverage the X overall at to milligrams There acne XX doses X were hours a XX% including nine XX daily milligrams looks six QD, studied the Nimbus volunteers and clinical IC-XX middle there milligrams and disorders to Phase of and IC-XX milligrams and hours. In X The QD. ranging we milligrams
IC-XX see consider clinic of milligrams and Patients have patients. hours coverage, up IC, about dermatitis to XX% great can XX doses, CP-X papular elevation if of coverage. the CPK of milligrams on rash to we five IC-XX You a hours XX% of XX room of relevant acneiform developed up XX and
Slide on XX. to Going
totality stepping focusing and from and relevant to the on on So healthy just data available volunteers the opportunities we're focusing doses. of the away here clinically
XXX findings. hours the the a the best-in-class and IC-XX, for and VTX-XXX, was maximize deucravacitinib opportunity BID XX what but believe for above window. not below hours coverage in psoriatic findings, achievable window, this dose of therapeutic leverage with And response of represents psoriasis because we So inflammatory only covering dose skin essentially that also limited bowel no XX therapeutic disease, arthritis to and no with laboratory of IC-XX
deucravacitinib, relevant the X coverage. QD, of no the IC-XX milligrams hours hours dose IC-XX nine of coverage, For of
dermatitis, doses milligrams especially apnea dependent as dose electrolyte acne more rash form X and than see You QD.
limiting. that's dose So
diseases. that hours of the rash and coverage that of I've IC-XX inflammatory are trials, why we're You CPK see and think psoriasis deucravacitinib, can triglyceride BID we more failed more the explained for where showed case five bowel as I X dose there to of and doses in elevations there opportunity coverage, only in to hours skin you IL-XX/IL-XX active elevation still that like and QD their a Phase was of And robust dose across products There's a some manifestations. think really see rare a wouldn't on this outcome and with see studied. response acne bowel neutropenia, there's and expect efficacy trial note dose have finally would the And milligram of been trial programs a disease And They go really XX we colitis. number was measures of CPK, limit, up linear they IC-XX for and of moment. coverage six the triglyceride they all that elevations. X PASI-XX that they Phase a relevant inflammatory aware currently of have that no in ulcerative milligrams XX an
Slide Moving to on XX.
here. that to of outcome achieving superior of at compounds XX% about PASI-XX directed PASI-XX. measures the the look the is to a low sort Deucravacitinib thought of third but range. TYKX only against interleukin commercial PASI-XX still range, XX% XX TYKX, a response sort see in rates let's is So IL-XX, for XX% and opportunity We've XX% can compounds of of biologic And as the for you the psoriasis. currently best-in-class
is you with a with the VTX-XXX much superior can is IC-XX target so target and for there's coverage what the Deucravacitinib gap see biologic cover therapies, gap achieved our So what a large a between can we close of because with that aspirational they're day. X dose where for milligram, day of once to
XX. Slide on Moving to
we think coverage for biologic read that we higher to IBD, is through agents know and higher target from doses on Focusing that required Crohn's disease.
and can if Crohn's You this greater with colitis other at doses versus that's exposures six biologics it noted hours biologic and required to skin from Tremfya of that as drugs despite six efficacy as fact efficacy inhibition will already you effects, need IC-XX with we and that side that Psoriasis see disease ulcerative four to Skyrizi, much X failed that disease well Deucravacitinib you I for Stelara the for here Phase the for suggests pathway higher required in efficacy coverage. times TYKX know psoriasis. Crohn's milligrams be in there's that associated IBD BID see zero already that dosing. But six do
antibody of Higher suppression results. So opportunity. doses may this Crohn's currently unexpected the of greater disease, $XX because pathway. this is opportunity And sort market than major is the or a of VTX-XXX global IL-XX biologic billion of a and like in of profile which VTX-XXX monoclonal this, IL-XX unlock may profile, approach
to Moving XX. Slide on
how we selection think dose of X broad the trials and about finding of we on later began year explore do target that range in based will opportunities, studies next So terms dose enabling this development Phase safety coverage. optimal what's Phase X will a maximizing the
the development X psoriasis, be dosed a could to unique proposition. solid with Rinvoq before was X. looking an X this it see X, profile or to of Specifically, in tablet. would Phase we in additional disease precedent indications we the which immediate And exposures a other lupus, And include also pursue There's in this BID and psoriatic post given year initiate arthritis. is at formulation as for Modified straightforward QD release Xeljanz trials VTX-XXX. trials Crohn's Phase we will Phase This and the the bridging done and Phase fourth study with IR release quarter plan three approximate of We're this, drugs. mortem. with in world
Slide XX. on Moving to
IL-XX IL-XX, same IL-XX as strong anticipate could target landscape in and VTX-XXX. for And agents well. So of aspirational IL-XX up? and Apremilast, the shows similarly, efficacy This and do We for very target we've as wrap with how discussed, the the the arthritis agents believe strong biologics with product that we Deucravacitinib, already coverage those we the see and see our profile does oral treatment we VTX-XXX for you and psoriasis this psoriatic VTX-XXX.
or disease IL-XX but data can't you use applicable We unlikely showed X like ulcerative what IL-XX For Crohn's VTX-XXX probably Crohn's I will yet on you that speculate disease, to at know or we not the the think a based I we a colitis, disease, ulcerative and finally Apremilast. for are don't story looking in effect. lupus. anti XX Deucravacitinib, best is really studies earlier, class, milligrams be effective once for Same have in whereas would that day colitis, biologic BID to accepted milligrams in Crohn's
And opportunity point in we therapeutic coverage, of bowel lupus. psoriatic the on safety across potentially and each well to impact this dominated to in indications. several smaller United This the TYKX $XX these these positioned almost if this biologic right excellent patients compared these that dominated leading Crohn's we're you contributions disease, and markets is on disease an XX is earlier, There's to psoriasis, opportunity in have was just ulcerative has a the superior make slide, arthritis States to the said And million markedly capitalize profile and previous else inflammatory markets. colitis I So markets. on are the as anything a classes. almost by we billion to Slide as make the world market. from VTX-XXX Raju unique window and showed class big, summarize XX; global autoimmune
at inhibitors and proven Crohn's what among a is IL-XX/IL-XX therapeutic to profile can with lupus two and enable greater narrow IBD in the and be by where multiple antibodies a TYK So psoriatic positioned arthritis than be differentiation address levels dosing IL-XX clinical psoriasis, to VTX-XXX, you indications TYK disease is inhibition across competitors, window are effective of differentiated higher than will do. has achieved with potential doses that more uniquely that offer indications that clinical
and move I here Raju will to stop back to hand it Please XX. to up. wrap on And so, Slide
